Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.078 AUD | +30.00% | -2.50% | -3.70% |
Mar. 20 | Australia's Tax Agency Publishes Ruling on Invex Therapeutics' Capital Return | MT |
Feb. 16 | Invex Therapeutics Narrows Fiscal H1 Loss on Lower R&D Expenses | MT |
Sales 2022 | 182K 120K | Sales 2023 | 459K 303K | Capitalization | 15.03M 9.91M |
---|---|---|---|---|---|
Net income 2022 | -3M -1.98M | Net income 2023 | -7M -4.61M | EV / Sales 2022 | 43.1 x |
Net cash position 2022 | 29.34M 19.33M | Net cash position 2023 | 22.47M 14.81M | EV / Sales 2023 | -16.2 x |
P/E ratio 2022 |
-9.41
x | P/E ratio 2023 |
-1.94
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 40.21% |
1 day | +30.00% | ||
1 week | -2.50% | ||
Current month | -2.50% | ||
3 months | -10.34% | ||
6 months | +4.00% | ||
Current year | -3.70% |
Managers | Title | Age | Since |
---|---|---|---|
Narelle Warren
DFI | Director of Finance/CFO | - | 19-02-28 |
Carol Parish
COO | Chief Operating Officer | - | - |
Thomas Duthy
BRD | Director/Board Member | - | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
David McAuliffe
CHM | Chairman | 58 | 19-03-07 |
Narelle Warren
DFI | Director of Finance/CFO | - | 19-02-28 |
Thomas Duthy
BRD | Director/Board Member | - | 20-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.078 | +30.00% | 182,550 |
24-06-06 | 0.06 | -23.08% | 83,219 |
24-06-05 | 0.078 | +2.63% | 210 |
24-06-04 | 0.076 | -5.00% | 68,200 |
24-06-03 | 0.08 | 0.00% | 6,321 |
Delayed Quote Australian S.E., June 06, 2024 at 08:23 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-3.70% | 3.86M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- IXC Stock